The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
make of it what you will but in the absence of any rns or capital market day that i know of it seems a back of a *** packet view to be honest:
'double-downgrade' from barclays.
the investment banking arm of the high-street lender moved to 'underweight' on stock in the long-term savings and retirement group with a price target of £5 a share.
in a brief note, it said: "phoenix faces insufficient cash from operations alone to support management's targets, a weaker capital position than peers, and a change in strategy from historical areas of strength to areas where the group is not meaningfully differentiated, in our view. targets may only be fully evident in 2027."
Https://www.polarean-ir.com/docs/librariesprovider37/archive/admission-doc.pdf
page 16 and page 50 are the key areas.
Los ... That is simple wrong. Read the IPO admission document and see the breakdown of the patents, expiry's and licence agreements. Duke own the vast majority and a lot due to expire in the next few years, hence hatchwaxman application and protection. There is a reason the CTO is from Duke and it involves risk free funding streams for their research. Polx own parts of the polariser but not the methodology. The IPO doc is detailed, as it had to be transparent from them to be listed. A company website... well ..enough said.
Different strategy for me...fully loaded for the following reasons:
1. Yield is covered and dividend policy will be progressive.
2. The company balance sheet will continue to generate FCF given forward earnings not accounted for
3. unemployment rate up and inflation nailed on to be lower tomorrow putting pressure on BofE
4. £ taking a hit and increasingly attractive returns to US based investors after their index meltdown
5. I just like the company
GLA
Proactive Investors - A competition probe into Britain’s veterinary market is unlikely to hit CVS Group (LON:CVSG) and Pets at Home Group PLC (LON:PETSP) as hard as feared, analysts have reassured.
The Competition and Markets Authority would likely look to enforce more transparency, rather than taking drastic measures such as forcing disposals and capping product prices, Liberum analysts said in a note.
“The main remedies are likely to be around information disclosure and there is nothing to stop the industry adopting those changes ahead of time,” the bank reassured, having interviewed the regulator’s ex-legal head, Tom Smith.
“The read across for CVS is perhaps less significant than one might have thought and contrary to some commentators, we don’t think that CVS is dead money.
“For Pets at Home, the impact is likely to be negligible with its differentiated model insulating it to a large degree.”
Britain’s CMA launched an investigation into the pet medicines and treatment market last month, warning owners were often uninformed on pricing and could be overpaying as a result.
AIM-listed vet service provider CVS Group took a hit on the news, having responded saying it had already proposed a “package of possible remedies” to the CMA.
Pets at Home assured the investigation was unlikely to find it at fault meanwhile, since the retailer’s sites run as joint ventures and are independently responsible for pricing.
Liberum, quoting Smith, argued that competition concerns were likely more a result of consumers not shopping around, given the often stressful nature of seeking pet care.
“If your dog is sick, you just want to get it sorted out,” as per Smith, “you don't want to go and shop around at four different vets to get different prices”.
Remedies are likely to tackle the lack of information on rival services and products, therefore, as per Liberum.
CVS climbed 2.4% to 967p on the news, while Pets at Home gained 1.1% to reach 268.59p.
I've been buying to top up and getting under the bid price ... that doesn't happen often but I'll take it at over 10% yield..
This is just being walked down with algo trades... 10% down is a nasty consolidation if it stops here. Surprised to be honest so averaged up again
I told you all last year how this would play out... sorry of those genuinely sucked in but I got a lot of abuse for the following :
29th Sept 2023 'Simple answer - draper secures the tech on a three year licence deal ...this company de-lists in which case the licence still stands but the payables become a grey area if this company goes into liquidation. in simple terms there is a life raft leaving but Mr Draper wants you to believe he is still the captain of this ship.... seems to me he is holding oars already ...'